Want To Keep Your Liver Healthy? Expert Reveals How Sleep And Avoiding Junk Food Can Help
New Delhi: Having a good night's sleep and avoiding junk food is essential to keep the liver healthy, said Dr. S.K. Sarin, Director of the Institute of Liver and Biliary Sciences (ILBS) on Friday.
He said that junk food, as the name suggests, must be put in dustbins as its regular consumption can significantly affect liver health.
'The word junk food means it is junk. It has to be put in the dustbin. But if you think your stomach and intestines are dustbins, put that food inside. Otherwise, avoid, don't use it,' Sarin said, in a post on social media platform X.
Junk food which is rich in unhealthy fats, sugars, and processed ingredients increases the risk of obesity, high cholesterol, and type 2 diabetes. These diseases then raise the chances of non-alcoholic fatty liver disease (NAFLD), and progress to more serious complications like cirrhosis and liver cancer.
Sarin also urged people to sleep well and not eat late as it may affect the gut bacteria, critical for better health. Studies have shown that people with poor sleep are at increased risk of fatty liver disease.
Further, eating late at night has been linked to a higher risk of significant fibrosis -- a sign of liver damage. It is because the body is unable to process fat and carbohydrates during sleep, leading to their accumulation in the liver.
'Sleeping late and eating late-night food is not a great idea, because the bacteria in your intestines which process the food, will also sleep late. Restorative good sleep is the best thing,' the leading hepatologist said.
Sarin advised people to not lose their health by running after 'money, power and positions'. Instead maintaining 'a sound healthy body and good night's sleep' is essential as these are the 'only two things which give happiness in life', the expert said.
NAFLD, currently termed metabolic dysfunction-associated steatotic liver disease (MASLD), is a chronic liver disease that occurs when fat builds up in the liver in people who don't drink much alcohol. It can affect people with diabetes, obesity, high blood pressure, or high cholesterol.
Fatty liver disease is emerging as an important cause of liver disease in India, affecting about three in 10 people in the country.
In September last year, the Union Health Ministry released the revised operational guidelines and training module for MAFLD to promote early detection and help boost patient care and outcomes related to the disease.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
5 hours ago
- Economic Times
This disease might be silently killing millions quietly, says research. Are you at risk?
A new international study has found that over 15 million people across the US, UK, Germany, and France are unknowingly living with metabolic dysfunction-associated steatohepatitis (MASH), the most aggressive form of fatty liver disease. Despite its serious risks—including liver failure, cancer, and other chronic illnesses—more than three-quarters of affected individuals remain undiagnosed. Researchers are urging wider screening, especially among those with obesity and type 2 diabetes, and highlighting the potential role of weight-loss medications in treatment. Tired of too many ads? Remove Ads Widespread but Largely Undetected Progressive and Potentially Fatal Tired of too many ads? Remove Ads Urgent Need for Diagnosis and Treatment Potential Role of Weight Loss Medications Risk Factors and Screening A recent international study has revealed that millions of people in the US and Europe may be unknowingly living with a dangerous form of fatty liver disease. Published in The Lancet Regional Health Europe, the research indicates that a vast number of individuals are affected by metabolic dysfunction-associated steatotic liver disease (MASLD), with the majority still study examined populations in the United States, United Kingdom, Germany, and France, and found that approximately 20 million people across these countries have the more severe variant of MASLD known as metabolic dysfunction-associated steatohepatitis (MASH). Alarmingly, only about 2.5 million have received a formal diagnosis. This means roughly three-quarters of those with the disease—an estimated 16.7 million individuals—remain unaware of their is the updated term for non-alcoholic fatty liver disease (NAFLD), and it affects people whose liver contains over 5% fat despite little or no alcohol intake. While many patients only develop the earliest and less severe stage known as simple fatty liver, the disease can progress without symptoms and cause serious damage over the aggressive form of the disease, is associated with inflammation and can lead to fibrosis, or scarring of the liver. If not managed, it may progress to cirrhosis, a stage marked by irreversible liver damage and potential liver failure. The condition is also linked to higher risks of cardiovascular issues, chronic kidney disease, and liver study's findings emphasize the urgency of early diagnosis, especially as MASH is particularly common among people with type 2 diabetes and those who are overweight or obese. Researchers noted that around two-thirds of individuals with type 2 diabetes are thought to have Jeffrey Lazarus, the lead author of the study, stressed the economic and health burden posed by undiagnosed MASH. He pointed out that without a significant increase in diagnosis and treatment, the financial costs to healthcare systems could triple over the next two Emmanouil Tsochatzis of University College London echoed this warning, stating that over 15 million people in the US and Europe are living with the most severe form of fatty liver disease without knowing it. He warned that both human suffering and economic consequences could worsen significantly if diagnosis rates do not MASH has been diagnosed through liver biopsy, but newer, non-invasive tools such as blood tests, ultrasound, and MRI scans have made screening easier. Experts now recommend that individuals with type 2 diabetes, obesity combined with other risk factors, or persistently elevated liver enzymes undergo regular study has also brought renewed attention to the potential of weight loss medications to help manage MASH. Dr. Paul Brennan, a hepatologist and co-author of the study, highlighted the promise of GLP-1 agonists like Wegovy and Mounjaro. These drugs work by reducing appetite and slowing digestion, leading to weight loss, which in turn may help reduce fat accumulation and scar tissue in the Betel, president of the Fatty Liver Alliance, stressed that individuals with type 2 diabetes or obesity are often not screened for MASH until significant liver damage has occurred. He called for broader liver health assessments and, when appropriate, the use of weight loss drugs as part of a comprehensive treatment strategy.A separate study released around the same time found that the diabetes drug dapagliflozin not only helps reduce blood sugar but also lowers fat and scarring in the liver, suggesting another potential treatment to health authorities like the NHS, those at greater risk of MASLD include people who are overweight, have type 2 diabetes, high blood pressure, high cholesterol, metabolic syndrome, or are over the age of 50. Smoking and thyroid disorders may also increase the typically begin diagnosis with blood tests that show elevated liver enzymes. If abnormalities are detected, further assessments such as imaging scans or liver elastography (FibroScan) are used to evaluate liver fat and fibrosis the growing prevalence of MASLD and MASH, the study underscores the critical importance of early screening, timely intervention, and broader public health awareness to address this hidden but escalating health threat.
Time of India
8 hours ago
- Time of India
This disease might be silently killing millions quietly, says research. Are you at risk?
A recent international study has revealed that millions of people in the US and Europe may be unknowingly living with a dangerous form of fatty liver disease. Published in The Lancet Regional Health Europe, the research indicates that a vast number of individuals are affected by metabolic dysfunction-associated steatotic liver disease (MASLD), with the majority still undiagnosed. Widespread but Largely Undetected The study examined populations in the United States, United Kingdom, Germany, and France, and found that approximately 20 million people across these countries have the more severe variant of MASLD known as metabolic dysfunction-associated steatohepatitis (MASH). Alarmingly, only about 2.5 million have received a formal diagnosis. This means roughly three-quarters of those with the disease—an estimated 16.7 million individuals—remain unaware of their condition. MASLD is the updated term for non-alcoholic fatty liver disease (NAFLD), and it affects people whose liver contains over 5% fat despite little or no alcohol intake. While many patients only develop the earliest and less severe stage known as simple fatty liver, the disease can progress without symptoms and cause serious damage over time. Progressive and Potentially Fatal MASH, the aggressive form of the disease, is associated with inflammation and can lead to fibrosis, or scarring of the liver. If not managed, it may progress to cirrhosis, a stage marked by irreversible liver damage and potential liver failure. The condition is also linked to higher risks of cardiovascular issues, chronic kidney disease, and liver cancer. The study's findings emphasize the urgency of early diagnosis, especially as MASH is particularly common among people with type 2 diabetes and those who are overweight or obese. Researchers noted that around two-thirds of individuals with type 2 diabetes are thought to have MASLD. Urgent Need for Diagnosis and Treatment Dr. Jeffrey Lazarus, the lead author of the study, stressed the economic and health burden posed by undiagnosed MASH. He pointed out that without a significant increase in diagnosis and treatment, the financial costs to healthcare systems could triple over the next two decades. Prof. Emmanouil Tsochatzis of University College London echoed this warning, stating that over 15 million people in the US and Europe are living with the most severe form of fatty liver disease without knowing it. He warned that both human suffering and economic consequences could worsen significantly if diagnosis rates do not improve. Traditionally, MASH has been diagnosed through liver biopsy, but newer, non-invasive tools such as blood tests, ultrasound, and MRI scans have made screening easier. Experts now recommend that individuals with type 2 diabetes, obesity combined with other risk factors, or persistently elevated liver enzymes undergo regular screening. Potential Role of Weight Loss Medications The study has also brought renewed attention to the potential of weight loss medications to help manage MASH. Dr. Paul Brennan, a hepatologist and co-author of the study, highlighted the promise of GLP-1 agonists like Wegovy and Mounjaro. These drugs work by reducing appetite and slowing digestion, leading to weight loss, which in turn may help reduce fat accumulation and scar tissue in the liver. Michael Betel, president of the Fatty Liver Alliance, stressed that individuals with type 2 diabetes or obesity are often not screened for MASH until significant liver damage has occurred. He called for broader liver health assessments and, when appropriate, the use of weight loss drugs as part of a comprehensive treatment strategy. A separate study released around the same time found that the diabetes drug dapagliflozin not only helps reduce blood sugar but also lowers fat and scarring in the liver, suggesting another potential treatment pathway. Risk Factors and Screening According to health authorities like the NHS, those at greater risk of MASLD include people who are overweight, have type 2 diabetes, high blood pressure, high cholesterol, metabolic syndrome, or are over the age of 50. Smoking and thyroid disorders may also increase the risk. Doctors typically begin diagnosis with blood tests that show elevated liver enzymes. If abnormalities are detected, further assessments such as imaging scans or liver elastography (FibroScan) are used to evaluate liver fat and fibrosis levels. With the growing prevalence of MASLD and MASH, the study underscores the critical importance of early screening, timely intervention, and broader public health awareness to address this hidden but escalating health threat.
The Hindu
10 hours ago
- The Hindu
Active COVID-19 cases cross 5,000; Centre steps up preparedness measures
India's active COVID-19 caseload crossed the 5,000-mark, with Kerala continuing to report the highest number of infections, followed by Gujarat, West Bengal, and Delhi, according to data released by the Union Health Ministry on Friday (June 6, 2025). In view of the uptick in cases, the Centre has initiated mock drills to assess facility-level preparedness across the country. All States have been directed to ensure the availability of oxygen, isolation beds, ventilators, and essential medicines in anticipation of any further rise in cases. The country currently has 5,364 active COVID-19 cases. Four new deaths linked to the infection were reported in the last 24 hours. Official sources have maintained that 'most cases are mild and managed under home care.' Also read: Misinformation a bigger threat than COVID-19 uptick Since January this year, a total of 55 deaths have been reported nationwide. The number of active cases stood at 257 as of May 22. A series of technical review meetings were held on June 2 and 3 under the chairpersonship of Dr. Sunita Sharma, Director General of Health Services (DGHS). The meetings were attended by representatives of the Disaster Management Cell, Emergency Management Response (EMR) Cell, National Centre for Disease Control (NCDC), Indian Council of Medical Research (ICMR), Integrated Disease Surveillance Programme (IDSP), Central Government Hospitals in Delhi, and officials from States and Union Territories, to assess the current COVID-19 situation and preparedness strategies. On June 4, official sources stated that State and District surveillance units under IDSP are closely monitoring trends in Influenza-Like Illness (ILI) and Severe Acute Respiratory Illness (SARI). 'Testing is recommended for all admitted SARI cases and 5 per cent of ILI cases as per guidelines, and positive SARI samples are sent for Whole Genome Sequencing through the ICMR VRDL network,' an official source said.
